Drugs / carmoterol
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01070524 | Jan → Jul 2010 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00782535 | Dec 2008 → Mar 2009 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00640484 | Apr → Oct 2008 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00605891 | Oct 2006 → Jun 2007 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carmoterol | “CHF 5188: fixed combination budesonide/carmoterol” NCT01070524 ↗ |
| Known as | CHF 4226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00782535 ↗ |
| Known as | Quinoterol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1094785 ↗ |
| Known as | TA-2005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1094785 ↗ |
| Action | Activate | “Beta-2 adrenergic receptor agonist” CHEMBL1094785 ↗ |
| Modality | Small molecule | — CHEMBL1094785 ↗ |
| Route | Inhaled | “carmoterol pMDI 2.0 μg once a day, in the morning” NCT00605891 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL1094785 ↗ |